Genomic analyses and novel models validate CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans

被引：0
|
作者：
Marino-Enriquez, Adrian [1 ,2 ]
Eilers, Grant [1 ,2 ]
Czaplinski, Jeffrey [2 ,3 ]
Mayeda, Mark [1 ,2 ]
Tao, Derrick [1 ,2 ]
Zhu, Meijun [1 ,2 ]
Hornick, Jason L. [1 ,2 ]
Sicinska, Ewa [2 ,3 ]
Wagner, Andrew J. [2 ,3 ]
Fletcher, Jonathan A. [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-607
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
607
引用
收藏
页数：3
相关论文
共 12 条
  • [1] CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
    Eilers, Grant
    Czaplinski, Jeffrey T.
    Mayeda, Mark
    Bahri, Nacef
    Tao, Derrick
    Zhu, Meijun
    Hornick, Jason L.
    Lindeman, Neal I.
    Sicinska, Ewa
    Wagner, Andrew J.
    Fletcher, Jonathan A.
    Marino-Enriquez, Adrian
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (06) : 1346 - 1353
  • [2] CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease
    Hashimoto, Hiroki
    Kaku-Ito, Yumiko
    Oda, Yoshinao
    Ito, Takamichi
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
    Dai, Meiou
    Zhang, Chenjing
    Ali, Ayad
    Hong, Xinyuan
    Tian, Jun
    Lo, Chieh
    Fils-Aime, Nadege
    Burgos, Sergio A.
    Ali, Suhad
    Lebrun, Jean-Jacques
    SCIENTIFIC REPORTS, 2016, 6
  • [4] Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
    Kase, Adam M.
    Copland, John A., III
    Tan, Winston
    ONCOTARGETS AND THERAPY, 2020, 13 : 10499 - 10513
  • [5] Targeting cellular pH as a novel therapeutic strategy in CDK4/6 inhibitor resistant breast cancer
    Scheidemann, Erin R.
    Demas, Diane M.
    Shajahan-Haq, Ayesha N.
    CANCER RESEARCH, 2024, 84 (06)
  • [6] CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
    Meiou Dai
    Chenjing Zhang
    Ayad Ali
    Xinyuan Hong
    Jun Tian
    Chieh Lo
    Nadège Fils-Aimé
    Sergio A. Burgos
    Suhad Ali
    Jean-Jacques Lebrun
    Scientific Reports, 6
  • [7] INHIBITION OF THE ATR PATHWAY AND CDK4/6 SIGNALLING AS NOVEL THERAPEUTIC STRATEGIES FOR METHOTREXATE-RESISTANT CHORIOCARCINOMA
    Pardo, O.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 200 - 200
  • [8] PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER plus /RB-deficient breast cancer
    Lin, Chang-Ching
    Chang, Tsung-Cheng
    Wang, Yunguan
    Guo, Lei
    Gao, Yunpeng
    Bikorimana, Emmanuel
    Lemoff, Andrew
    Fang, Yisheng V.
    Zhang, He
    Zhang, Yanfeng
    Ye, Dan
    Soria-Bretones, Isabel
    Servetto, Alberto
    Lee, Kyung-min
    Luo, Xuemei
    Otto, Joseph J.
    Akamatsu, Hiroaki
    Napolitano, Fabiana
    Mani, Ram
    Cescon, David W.
    Xu, Lin
    Xie, Yang
    Mendell, Joshua T.
    Hanker, Ariella B.
    Arteaga, Carlos L.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [9] Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers
    Navarro-Yepes, Juliana
    Chen, Xian
    Bui, Tuyen
    Kettner, Nicole M.
    Hunt, Kelly K.
    Keyomarsi, Khandan
    CANCER RESEARCH, 2020, 80 (04)
  • [10] Combination of ZEN-3694 with talazoparib is a novel therapeutic approach in ER positive breast cancer resistant to CDK4/6 inhibitors, independent of BRCA status.
    Kharenko, Olesya A.
    Patel, Reena
    Calosing, Cyrus
    CANCER RESEARCH, 2021, 81 (13)
12